Thus far, we know that in the SEARCH-AF trial, among patients with DM, SGLT-2 inhibitors—compared to other glucose-lowering therapies—led to the lowest 30-day POAF incidence [27]. This evidence concerns the gene SLC5A2 and atrial fibrillation.